PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation
about
P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARalpha-mediated transcriptionFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaRetinoic acid and arsenic for treating acute promyelocytic leukemiaCross-platform analysis of cancer microarray data improves gene expression based classification of phenotypesPerspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogsIdentification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia.Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYCPML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA associationCharacterisation of genome-wide PLZF/RARA target genes.The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.The PML domain of PML-RARα blocks senescence to promote leukemiaGlucocorticoid receptor cofactors as therapeutic targets.MIR125B1 represses the degradation of the PML-RARA oncoprotein by an autophagy-lysosomal pathway in acute promyelocytic leukemia.cFos mediates cAMP-dependent generation of ROS and rescue of maturation program in retinoid-resistant acute promyelocytic leukemia cell line NB4-LR1.Aberrant corepressor interactions implicated in PML-RAR(alpha) and PLZF-RAR(alpha) leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants.Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7.Dominant-negative mechanism of leukemogenic PAX5 fusions.In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.Acute promyelocytic leukemia: a model of molecular target based therapy.Transcriptional repression of CDKN2D by PML/RARα contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells.PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia.Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.Regulation of antimicrobial peptide gene expression by nutrients and by-products of microbial metabolism.Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.Epigenetic regulation of normal and malignant hematopoiesis.NLS-RARα Inhibits the Effects of All-trans Retinoic Acid on NB4 Cells by Interacting with P38α MAPK.Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent mannerThe molecular signature of oncofusion proteins in acute myeloid leukemia.Towards novel paradigms for cancer therapy.Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.Genome-wide functions of PML-RARα in acute promyelocytic leukaemiaEffects of PPARγ Ligands on Leukemia.Origins of aberrant DNA methylation in acute myeloid leukemia.Differentiation therapy of acute myeloid leukemia.RARA fusion genes in acute promyelocytic leukemia: a review.Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia.Computational identification of the normal and perturbed genetic networks involved in myeloid differentiation and acute promyelocytic leukemia.Molecular signature of retinoic acid treatment in acute promyelocytic leukemia.p53 as an Effector or Inhibitor of Therapy Response.
P2860
Q24303531-47820D46-9A04-4F18-9B18-049B3808452DQ24605527-1EDB0CC9-91E0-4571-8AF7-706BB021C0D1Q24809165-1252351A-D79D-4E0D-AC2B-09FFC258ADB9Q24811346-2F34E753-7CE4-4A41-AEA8-D9BC9CB3CA8BQ26991440-54D7B7C8-17AB-4F60-B465-D923E062031FQ33560404-13B656A3-EAE3-4C00-A9AE-35F2F5EF145CQ33560429-AC8F70C0-594F-4BFB-9C73-BCAF687999CCQ33734488-1AD6C055-082E-4546-B1D1-D9FC739F6816Q34031285-EDB869E0-8F04-45DA-B19A-2025C3344277Q34041515-BDF32449-46B6-426A-A083-FF5C865925A9Q34082734-CCC0D4DC-FDC6-48CA-A94B-6A291B5289A8Q34311390-1F7BF794-B73F-4154-97D2-EE4ABDE8E55BQ34344666-C30CED59-FD2E-42CC-9582-F2CE92CA6E13Q34500276-24B0B94C-6527-4548-B7E4-64F5124BB278Q34575940-AD191AE0-02DB-4986-9BE8-59A4A9653F2DQ34687054-A6FA6743-4DDD-4E02-A6B2-771EABFAF83DQ35402092-9C3247CA-88F5-4E7B-8C39-99CA3FA2705CQ36228502-AF71B918-7B48-4A51-BAE5-F3FD32185D2AQ36270144-11ABAD4C-3037-4A26-AC9B-AD284D4A0D94Q36291101-8AA1DD7E-A800-40C1-83AB-40726A78BE57Q36430688-9F12AAF1-0577-4F43-9BC5-5F3F1C85513AQ36478470-677F1708-D04D-454D-8936-4208CF18FC3DQ36655079-698CAC0E-6A51-46D2-B81E-893E7926A17CQ36732473-8EC2F04A-A7E8-4DA5-8A63-2D5BFAA2D6F7Q36970179-09622180-4ED4-48A9-852E-4847D198827CQ37154434-1CFE8742-7800-442A-AE03-23A17704F202Q37216371-2D8F7C9C-6996-40CB-9257-2598C9A0C876Q37707093-EFE2BDE8-F240-4B94-80C6-AAB1272402E0Q37730254-6618320B-A16E-43B9-B087-B21654F7AAF1Q37799251-D24616FC-5388-4DD8-802A-D069CBB07228Q37802188-E9947676-8917-470E-B841-FAC46800A224Q37829905-1157CD2A-A920-4C97-BB46-E537630ADA6BQ38017661-0E1875CA-035D-4DA0-A351-6B4F6C1AD16CQ38130091-1C8705B2-0506-499A-801E-2029CAE253D0Q38161360-B52168AF-54D6-4B8C-A0C7-498205A42FB9Q38203568-16CCD2B7-EBD7-491A-8EAE-38608B6A588AQ38240617-892E4D4F-F370-4694-9FCF-1EBD72D6BA2DQ38275870-792A2DAE-83F3-49A8-B113-634B2DD33296Q38329965-0ABDA09E-D0AD-4291-9AD7-9C2EF9C1FCE5Q38659283-665BD86C-063F-47D1-A99F-3DE358D8277E
P2860
PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
PML-RARA-RXR oligomers mediate ...... leukemia cell differentiation
@en
type
label
PML-RARA-RXR oligomers mediate ...... leukemia cell differentiation
@en
prefLabel
PML-RARA-RXR oligomers mediate ...... leukemia cell differentiation
@en
P2093
P2860
P356
P1476
PML-RARA-RXR oligomers mediate ...... leukemia cell differentiation
@en
P2093
Dmitrii Kamashev
Dominique Vitoux
Hugues De Thé
P2860
P304
P356
10.1084/JEM.20032226
P407
P577
2004-04-01T00:00:00Z